Index - P/E - EPS (ttm) - Insider Own - Shs Outstand 38.32M Perf Week 0.22%
Market Cap 723.78M Forward P/E - EPS next Y - Insider Trans - Shs Float 21.49M Perf Month -
Income - PEG - EPS next Q - Inst Own 10.05% Short Float - Perf Quarter -
Sales - P/S - EPS this Y - Inst Trans - Short Ratio - Perf Half Y -
Book/sh -7.54 P/B - EPS next Y - ROA - Short Interest - Perf Year -
Cash/sh 4.62 P/C 3.94 EPS next 5Y - ROE - 52W Range 17.02 - 18.99 Perf YTD 0.22%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -4.21% Beta -
Dividend TTM - Quick Ratio 4.82 Sales past 5Y - Gross Margin - 52W Low 6.87% ATR (14) 0.97
Dividend Ex-Date Dec 24, 2019 Current Ratio 4.82 EPS Y/Y TTM - Oper. Margin - RSI (14) - Volatility - -
Employees - Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom - Target Price -
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q - Payout - Rel Volume 0.12 Prev Close 17.52
Sales Surprise - EPS Surprise - Sales Q/Q - Earnings - Avg Volume 507.43K Price 18.19
SMA20 2.00% SMA50 2.00% SMA200 2.00% Trades
Volume 52,858 Change 3.82%
Sep-19-24 04:15PM
Sep-13-24 04:09PM
12:19AM
Sep-12-24 10:37PM
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Enavate Sciences GP, LLC 10% Owner Sep 16 '24 Buy 17.00 882,353 15,000,001 3,761,359 Sep 18 04:15 PM Lu Hongbo Director Sep 13 '24 Buy 17.00 58,823 999,991 58,823 Sep 17 07:52 PM ENRIGHT PATRICK G Director Sep 16 '24 Buy 17.00 440,000 7,480,000 774,530 Sep 16 08:57 PM Nunn Jason Raleigh Director Sep 16 '24 Buy 17.00 882,352 14,999,984 1,946,564 Sep 16 08:54 PM Fairmount Funds Management LLC Director Sep 16 '24 Buy 17.00 300,000 5,100,000 1,604,891 Sep 16 08:54 PM SR ONE CAPITAL MANAGEMENT, LLC 10% Owner Sep 16 '24 Buy 17.00 2,235,294 37,999,998 1,946,564 Sep 16 08:51 PM
Index RUT P/E - EPS (ttm) -1.31 Insider Own 29.28% Shs Outstand 64.58M Perf Week 12.95%
Market Cap 854.11M Forward P/E - EPS next Y -1.38 Insider Trans -0.46% Shs Float 59.72M Perf Month 28.36%
Income -95.89M PEG - EPS next Q -0.34 Inst Own 59.53% Short Float 4.45% Perf Quarter 39.90%
Sales 0.00M P/S - EPS this Y -1.07% Inst Trans 23.17% Short Ratio 1.38 Perf Half Y 54.43%
Book/sh 3.11 P/B 3.25 EPS next Y -7.14% ROA -36.84% Short Interest 2.66M Perf Year 97.56%
Cash/sh 2.67 P/C 3.79 EPS next 5Y - ROE -38.92% 52W Range 3.26 - 11.40 Perf YTD 55.86%
Dividend Est. - P/FCF - EPS past 5Y -12.40% ROI -43.85% 52W High -11.27% Beta -0.38
Dividend TTM - Quick Ratio 21.02 Sales past 5Y -20.00% Gross Margin - 52W Low 210.28% ATR (14) 0.88
Dividend Ex-Date - Current Ratio 21.02 EPS Y/Y TTM -2.14% Oper. Margin 0.00% RSI (14) 61.35 Volatility 8.40% 9.39%
Employees 66 Debt/Eq 0.00 Sales Y/Y TTM -100.00% Profit Margin - Recom 1.29 Target Price 19.50
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q -21.77% Payout - Rel Volume 0.77 Prev Close 10.04
Sales Surprise - EPS Surprise 8.58% Sales Q/Q - Earnings Aug 05 AMC Avg Volume 1.92M Price 10.11
SMA20 16.31% SMA50 22.55% SMA200 48.08% Trades
Volume 1,253,630 Change 0.75%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-22-23 Initiated Mizuho
Buy
$16
Jun-07-23 Initiated Jefferies
Buy
$18
May-31-23 Initiated ROTH MKM
Buy
$23
May-08-23 Initiated BMO Capital Markets
Outperform
$18
Feb-14-23 Initiated JMP Securities
Mkt Outperform
$17
Feb-07-23 Initiated UBS
Buy
$19
Sep-12-22 Initiated H.C. Wainwright
Neutral
$6
Sep-14-21 Resumed Goldman
Buy
$21
Mar-02-21 Initiated JP Morgan
Overweight
$32
Mar-02-21 Initiated Goldman
Buy
$29
Mar-02-21 Initiated Cowen
Outperform
Show Previous Ratings
Sep-18-24 10:07AM
Sep-17-24 01:30AM
Sep-15-24 07:21AM
06:09AM
Sep-14-24 10:12AM
07:00PM
Loading…
Sep-12-24 07:00PM
(GlobeNewswire) -10.96%
-5.84%
Sep-10-24 10:50PM
04:52AM
Sep-09-24 04:01PM
09:58AM
09:24AM
08:06AM
07:05AM
Aug-28-24 09:55AM
Aug-05-24 09:56PM
04:05PM
Loading…
04:05PM
Aug-02-24 01:54PM
Aug-01-24 04:05PM
Jul-29-24 04:05PM
(GlobeNewswire) -7.55%
-7.92%
Jul-26-24 06:40PM
Jul-20-24 09:30AM
Jun-21-24 06:30PM
Jun-19-24 01:27PM
Jun-04-24 09:55AM
Jun-03-24 04:10PM
May-30-24 08:05AM
May-17-24 04:05PM
May-13-24 01:53PM
09:32AM
08:05AM
04:05PM
Loading…
May-08-24 04:05PM
May-07-24 04:05PM
May-03-24 04:05PM
Apr-29-24 04:05PM
Apr-10-24 04:05PM
Mar-14-24 04:05PM
(GlobeNewswire) -5.23%
+7.30%
Mar-11-24 04:05PM
Mar-07-24 04:05PM
Feb-27-24 04:05PM
(GlobeNewswire) +5.69%
-6.26%
Feb-07-24 04:05PM
(GlobeNewswire) +6.13%
+9.81%
08:05AM
Feb-02-24 04:05PM
Jan-04-24 04:05PM
Jan-03-24 04:05PM
Nov-29-23 04:05PM
Nov-27-23 04:05PM
Nov-14-23 12:16PM
08:05AM
Nov-13-23 08:05AM
Nov-09-23 08:05AM
Nov-03-23 04:05PM
Nov-02-23 04:05PM
Oct-19-23 04:05PM
Oct-16-23 08:05AM
Oct-03-23 04:05PM
Sep-06-23 04:05PM
Sep-05-23 04:05PM
Aug-08-23 04:15PM
04:05PM
Aug-03-23 06:00PM
05:05PM
Jul-28-23 07:01PM
Jul-18-23 04:05PM
Jul-05-23 04:05PM
Jun-26-23 04:05PM
(GlobeNewswire) -12.16%
-23.52%
Jun-06-23 04:30PM
Jun-02-23 04:05PM
May-28-23 09:45AM
May-25-23 05:05PM
May-24-23 04:05PM
May-22-23 04:05PM
(GlobeNewswire) +11.79%
+6.12%
May-15-23 08:05AM
May-09-23 04:05PM
May-03-23 04:05PM
Apr-25-23 12:00PM
Mar-30-23 02:28PM
Mar-27-23 04:05PM
(GlobeNewswire) +5.83%
+13.24%
08:05AM
Mar-08-23 05:26AM
Mar-02-23 04:05PM
Feb-26-23 10:51AM
Feb-08-23 12:00PM
Feb-02-23 04:05PM
Jan-12-23 04:05PM
Jan-05-23 04:05PM
Dec-23-22 04:05PM
(GlobeNewswire) -7.20%
+8.24%
Dec-20-22 07:40PM
08:05AM
Dec-19-22 04:31PM
Dec-01-22 04:05PM
(GlobeNewswire) -10.30%
-8.03%
Nov-16-22 09:31AM
Nov-09-22 04:05PM
(GlobeNewswire) -8.10%
-16.23%
Nov-04-22 08:05AM
Oct-26-22 04:05PM
Oct-12-22 05:26AM
Oct-11-22 04:05PM
Sep-29-22 06:03AM
Sep-21-22 05:33AM
Sep-07-22 04:05PM
Aug-19-22 06:50AM
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Lu Hongbo Director Sep 12 '24 Buy 10.50 476,190 4,999,995 476,190 Sep 17 07:48 PM Vignola Mark J. Chief Financial Officer Sep 10 '24 Option Exercise 5.36 10,000 53,600 101,940 Sep 12 06:10 PM Vignola Mark J. Chief Financial Officer Sep 10 '24 Sale 11.00 10,000 110,000 91,940 Sep 12 06:10 PM Quigley Jill M. Director Sep 09 '24 Option Exercise 1.82 17,235 31,368 32,235 Sep 11 06:00 PM Quigley Jill M. Director Sep 09 '24 Sale 10.00 17,235 172,350 15,000 Sep 11 06:00 PM SEOKHO BRYAN YOON Officer Sep 10 '24 Proposed Sale 9.12 10,000 91,200 Sep 10 04:21 PM MARK J VIGNOLA Officer Sep 10 '24 Proposed Sale 9.12 10,000 91,200 Sep 10 04:21 PM JILL QUIGLEY Officer Sep 09 '24 Proposed Sale 7.81 8,857 69,173 Sep 09 04:30 PM Quigley Jill M. Director Aug 02 '24 Sale 7.50 8,857 66,432 15,000 Aug 05 08:11 PM Quigley Jill M. Director Aug 01 '24 Sale 7.68 6,143 47,148 23,857 Aug 05 08:11 PM GORDON CARL L Director Jul 15 '24 Sale 10.00 50,976 509,760 756,258 Jul 17 08:53 PM GORDON CARL L Director Jul 16 '24 Sale 10.00 5,188 51,880 755,635 Jul 17 08:53 PM ORBIMED ADVISORS LLC Director Jul 15 '24 Sale 10.00 50,976 509,760 756,258 Jul 17 08:48 PM ORBIMED ADVISORS LLC Director Jul 16 '24 Sale 10.00 5,188 51,880 755,635 Jul 17 08:48 PM Quigley Jill M. Director Jul 15 '24 Option Exercise 1.82 14,365 26,144 44,365 Jul 17 07:56 PM Quigley Jill M. Director Jul 16 '24 Option Exercise 1.82 400 728 30,400 Jul 17 07:56 PM Quigley Jill M. Director Jul 15 '24 Sale 10.00 14,365 143,660 30,000 Jul 17 07:56 PM Quigley Jill M. Director Jul 16 '24 Sale 10.00 400 4,000 30,000 Jul 17 07:56 PM Vivo Opportunity, LLC 10% Owner Apr 01 '24 Sale 6.99 181,117 1,266,008 275,772 Apr 03 08:47 PM Vivo Opportunity, LLC 10% Owner Apr 03 '24 Sale 6.20 138,066 856,009 268,573 Apr 03 08:47 PM Vivo Opportunity, LLC 10% Owner Apr 02 '24 Sale 6.65 101,480 674,842 272,722 Apr 03 08:47 PM
Index RUT P/E - EPS (ttm) -4.65 Insider Own 4.68% Shs Outstand 124.31M Perf Week -2.32%
Market Cap 2.61B Forward P/E - EPS next Y -4.36 Insider Trans -0.24% Shs Float 118.50M Perf Month -16.84%
Income -538.64M PEG - EPS next Q -0.97 Inst Own 79.04% Short Float 7.30% Perf Quarter -17.68%
Sales 19.65M P/S 132.79 EPS this Y -137.89% Inst Trans -1.58% Short Ratio 8.20 Perf Half Y -25.64%
Book/sh 2.66 P/B 7.89 EPS next Y 4.51% ROA -64.14% Short Interest 8.65M Perf Year -22.29%
Cash/sh 3.51 P/C 5.98 EPS next 5Y 7.33% ROE -154.92% 52W Range 19.44 - 39.83 Perf YTD -31.40%
Dividend Est. - P/FCF - EPS past 5Y -24.19% ROI -69.18% 52W High -47.30% Beta 0.97
Dividend TTM - Quick Ratio 4.65 Sales past 5Y 205.96% Gross Margin 11.29% 52W Low 7.98% ATR (14) 1.17
Dividend Ex-Date - Current Ratio 4.65 EPS Y/Y TTM -173.09% Oper. Margin -2785.05% RSI (14) 40.20 Volatility 6.76% 5.28%
Employees 525 Debt/Eq 1.37 Sales Y/Y TTM -92.33% Profit Margin -2741.43% Recom 1.62 Target Price 45.54
Option/Short Yes / Yes LT Debt/Eq 1.36 EPS Q/Q -42.94% Payout - Rel Volume 0.60 Prev Close 21.14
Sales Surprise -100.00% EPS Surprise -160.92% Sales Q/Q -100.00% Earnings Aug 08 AMC Avg Volume 1.05M Price 20.99
SMA20 -6.76% SMA50 -15.58% SMA200 -22.89% Trades
Volume 541,343 Change -0.71%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-05-24 Initiated Goldman
Neutral
$31
Dec-04-23 Initiated BofA Securities
Buy
$29
Sep-19-23 Initiated Citigroup
Neutral
$33
Jul-21-23 Initiated TD Cowen
Outperform
May-12-23 Downgrade SVB Securities
Outperform → Market Perform
$40
Apr-26-23 Initiated SMBC Nikko
Outperform
$80
Apr-12-23 Upgrade SVB Securities
Market Perform → Outperform
$21 → $35
Mar-21-23 Initiated Bernstein
Mkt Perform
$27
Sep-09-22 Initiated Morgan Stanley
Equal-Weight
$41
May-11-22 Upgrade Robert W. Baird
Neutral → Outperform
$71 → $60
Jan-19-22 Resumed Goldman
Buy
$90 → $85
Aug-06-21 Reiterated Chardan Capital Markets
Buy
$97 → $94
Jun-04-21 Resumed Robert W. Baird
Neutral
$85
Feb-05-21 Reiterated H.C. Wainwright
Buy
$90 → $95
Dec-21-20 Downgrade Robert W. Baird
Outperform → Neutral
$75
Dec-16-20 Initiated UBS
Buy
$95
Nov-19-20 Initiated Citigroup
Buy
$90
May-13-20 Initiated RBC Capital Mkts
Outperform
$62
May-08-20 Upgrade Oppenheimer
Perform → Outperform
$58
Apr-15-20 Upgrade Cantor Fitzgerald
Neutral → Overweight
$55 → $60
Show Previous Ratings
Sep-11-24 06:12AM
(Pharmaceutical Technology)
Sep-10-24 07:30AM
Sep-03-24 10:36AM
06:33AM
Sep-02-24 06:36AM
07:30AM
Loading…
Aug-21-24 07:30AM
Aug-16-24 06:00AM
Aug-15-24 10:52AM
(Pharmaceutical Technology)
Aug-14-24 01:30PM
Aug-08-24 04:37PM
(Associated Press Finance)
-9.44%
04:01PM
04:00PM
Jul-29-24 04:30PM
Jul-24-24 07:30AM
Jun-28-24 06:50AM
01:55PM
Loading…
Jun-25-24 01:55PM
Jun-24-24 07:30AM
Jun-03-24 03:55PM
07:30AM
May-31-24 07:30AM
May-29-24 05:30AM
May-28-24 06:04AM
May-20-24 11:04AM
06:00AM
May-14-24 07:08AM
May-10-24 01:03PM
12:26PM
11:32AM
May-09-24 11:54PM
04:34PM
04:14PM
Loading…
04:14PM
(Associated Press Finance)
04:01PM
May-03-24 07:26AM
May-02-24 04:01PM
Apr-29-24 07:30AM
Apr-26-24 07:30AM
Apr-24-24 04:01PM
07:30AM
Apr-16-24 09:00AM
Apr-07-24 09:00AM
Apr-04-24 01:27AM
Apr-01-24 04:30PM
Mar-25-24 08:00AM
Mar-11-24 06:53PM
Mar-08-24 11:29PM
07:30AM
Mar-04-24 07:30AM
Feb-07-24 10:42AM
10:02AM
(Thomson Reuters StreetEvents)
Feb-06-24 04:32PM
(Associated Press Finance)
04:32PM
04:01PM
Jan-22-24 04:01PM
Jan-18-24 05:37AM
Jan-09-24 03:02AM
Jan-06-24 01:01PM
Jan-05-24 05:00PM
11:02AM
Jan-03-24 07:00AM
Dec-29-23 04:01PM
Dec-24-23 09:01AM
Dec-21-23 07:30AM
Dec-20-23 07:30AM
Dec-01-23 09:32AM
Nov-30-23 12:22PM
(Thomson Reuters StreetEvents) -26.85%
Nov-29-23 04:51PM
04:01PM
Nov-28-23 07:30AM
Nov-22-23 09:46PM
Nov-21-23 04:01PM
Nov-16-23 07:30AM
Nov-13-23 09:30AM
Nov-06-23 07:30AM
Nov-02-23 07:30AM
Oct-31-23 08:30AM
07:46AM
Oct-28-23 05:02AM
Oct-03-23 04:01PM
Sep-27-23 04:30PM
Sep-21-23 05:01AM
Sep-11-23 07:30AM
Sep-09-23 03:59PM
Sep-07-23 07:34PM
Sep-01-23 07:30AM
Aug-13-23 08:32AM
Aug-10-23 08:10AM
Aug-08-23 09:42AM
09:13AM
(Thomson Reuters StreetEvents)
06:20AM
Aug-07-23 04:16PM
04:01PM
Jul-24-23 04:00PM
Jul-17-23 07:30AM
Jul-06-23 04:30PM
Jun-30-23 06:52AM
Jun-27-23 07:30AM
Jun-24-23 08:15AM
Jun-21-23 08:00PM
Jun-14-23 06:34PM
Jun-06-23 07:30AM
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Oliver Tracie Chief Commercial Officer Jul 02 '24 Sale 25.28 9,394 237,480 127,107 Jul 03 05:27 PM Vakiener Victoria Director May 02 '24 Sale 23.31 1,799 41,935 30,205 May 06 06:04 PM Hamilton James C Chief Discovery/Trans Medicine Apr 01 '24 Sale 28.03 6,000 168,180 204,851 Apr 03 06:05 PM Lu Hongbo Director Mar 19 '24 Buy 28.00 1,000 28,000 32,680 Mar 20 07:06 PM Lu Hongbo Director Mar 20 '24 Buy 27.50 1,000 27,500 33,680 Mar 20 07:06 PM Lu Hongbo Director Mar 18 '24 Buy 27.49 1,000 27,490 31,680 Mar 20 07:06 PM Myszkowski Kenneth Allen Chief Financial Officer Mar 06 '24 Sale 35.19 40,000 1,407,600 400,600 Mar 08 05:54 PM Anzalone Christopher Richard Chief Executive Officer Jan 31 '24 Option Exercise 14.54 57,499 836,035 3,772,547 Feb 02 05:25 PM Anzalone Christopher Richard Chief Executive Officer Jan 31 '24 Sale 32.35 57,499 1,860,019 3,715,048 Feb 02 05:25 PM Hamilton James C Chief Discovery/Trans Medicine Jan 12 '24 Sale 36.89 7,940 292,904 210,851 Jan 17 06:32 PM GIVEN DOUGLAS B Director Jan 11 '24 Sale 38.06 2,911 110,788 129,711 Jan 16 06:06 PM Waddill William D. Director Jan 11 '24 Sale 38.07 3,934 149,759 47,870 Jan 16 06:06 PM Ferrari Mauro Director Jan 11 '24 Sale 38.06 3,147 119,787 60,778 Jan 16 06:06 PM Vakiener Victoria Director Jan 11 '24 Sale 38.10 4,720 179,813 32,001 Jan 16 06:06 PM Oliver Tracie Chief Commercial Officer Jan 05 '24 Sale 33.89 74 2,508 136,501 Jan 08 05:17 PM Myszkowski Kenneth Allen Chief Financial Officer Jan 05 '24 Sale 35.27 16,104 567,910 440,600 Jan 08 05:16 PM San Martin Javier Chief Medical Officer Jan 05 '24 Sale 35.26 8,303 292,804 198,497 Jan 08 05:16 PM Hamilton James C Chief Discovery/Trans Medicine Jan 05 '24 Sale 35.18 32,143 1,130,748 218,791 Jan 05 08:02 PM Hamilton James C Chief Discovery/Trans Medicine Jan 03 '24 Sale 32.19 6,300 202,781 175,934 Jan 05 08:02 PM O'Brien Patrick COO and General Counsel Jan 05 '24 Sale 35.27 22,841 805,716 464,385 Jan 05 07:58 PM O'Brien Patrick COO and General Counsel Jan 03 '24 Sale 32.28 8,749 282,439 403,826 Jan 05 07:58 PM O'Brien Patrick COO and General Counsel Jan 04 '24 Sale 32.63 1,600 52,208 402,226 Jan 05 07:58 PM Anzalone Christopher Richard Chief Executive Officer Jan 02 '24 Sale 31.01 9,952 308,637 3,715,048 Jan 04 05:25 PM Anzalone Christopher Richard Chief Executive Officer Dec 20 '23 Sale 28.54 12,000 342,480 3,725,000 Dec 22 05:04 PM San Martin Javier Chief Medical Officer Nov 20 '23 Sale 28.80 19,700 567,315 131,800 Nov 22 02:31 PM Anzalone Christopher Richard Chief Executive Officer Oct 25 '23 Sale 24.21 24,338 589,223 3,737,000 Oct 27 06:23 PM Vakiener Victoria Director Sep 28 '23 Sale 26.33 1,550 40,812 21,734 Oct 02 05:51 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
